ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021

Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer.

Katelyn T Byrne et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.